AbbVie Inc.

AbbVie Inc. is an American global research-based biopharmaceutical company that discovers, develops, manufactures, and sells innovative therapies across immunology, neuroscience, oncology, and aesthetics, generating $61.2 billion in GAAP net revenues in fiscal 2025. Spun out of Abbott Laboratories in 2013 and now employing roughly 57,000 people in over 70 countries, AbbVie is simultaneously one of the pharmaceutical industry's great Humira-succession stories and the owner of one of its most consequential concentration questions: roughly 42% of total revenues now come from two products — Skyrizi and Rinvoq — whose composition-of-matter patents expire in 2033.

The central arc here is the successful replacement of a declining mega-blockbuster. In 2023, Humira lost US market exclusivity after having been the world's best-selling drug for nearly a decade, peaking at over $20 billion in annual revenue. By fiscal 2025, Humira had fallen to $4.5 billion — a 49% year-on-year decline — yet AbbVie's total revenue grew 8.6% to $61.2 billion, surpassing its pre-LOE peak in just the second full year after the cliff. Skyrizi and Rinvoq, the two immunology assets built to succeed Humira, generated a combined $25.9 billion in 2025 and are guided to roughly $30 billion in 2026. This is a genuinely impressive commercial handoff.

The file turns on a different question: not whether management executed the Humira transition — they did — but whether the current valuation, which prices AbbVie at roughly $445 billion in market capitalization and $509 billion in enterprise value, appropriately discounts the concentration risk embedded in two products that lose patent protection within seven years, supported by a pipeline that, while broad, has yet to prove it can produce a third franchise of comparable scale.